Protein kinases are the molecular switches of the cell. They control growth, division, communication, and survival by ...

Protein kinases are the molecular switches of the cell. They control growth, division, communication, and survival by ...

The landscape of phosphodiesterase 3/4 (PDE3/4) inhibitors is experiencing a significant transformation in 2025, driven by ...

Investing.com -- Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock rose 4.5% on Monday after the FDA accepted the company’s application to expand the use of its psoriasis treatment to younger children.

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in child ...

Arcutis Biotherapeutics (ARQT) announced the FDA acceptance of a supplemental New Drug Application, sNDA, for ZORYVE cream 0.3%, a once-daily, ...

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical ...

Arcutis Biotherapeutics (ARQT) announced the enrollment of the last subject in the INTEGUMENT-INFANT Phase 2 open-label clinical study, which is ...

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic ...

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.

A scheme showing two complex organic molecules with multiple ring systems: the one on the left contains a four-sided ring with an oxygen in it, and the one on the left is identical except that the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Approximately 1.8 million children aged 2 to 5 years are ...